Monte Rosa Therapeutics Analyst Ratings
Monte Rosa Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 64.67% | Credit Suisse | → $11 | Reiterates | Neutral → Neutral |
| 05/12/2023 | 64.67% | Credit Suisse | → $11 | Reiterates | Neutral → Neutral |
| 03/17/2023 | 64.67% | Credit Suisse | $12 → $11 | Maintains | Neutral |
| 01/03/2023 | 184.43% | Wells Fargo | → $19 | Upgrades | Equal-Weight → Overweight |
| 10/13/2022 | 229.34% | UBS | → $22 | Initiates Coverage On | → Buy |
| 08/15/2022 | 199.4% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 05/12/2022 | 214.37% | Piper Sandler | $40 → $21 | Maintains | Overweight |
| 04/28/2022 | 184.43% | Credit Suisse | → $19 | Initiates Coverage On | → Neutral |
| 02/10/2022 | 184.43% | Wells Fargo | → $19 | Initiates Coverage On | → Equal-Weight |
| 10/14/2021 | 199.4% | SVB Leerink | → $20 | Initiates Coverage On | → Market Perform |
| 07/19/2021 | 349.1% | Guggenheim | → $30 | Initiates Coverage On | → Buy |
| 07/19/2021 | 498.8% | Piper Sandler | → $40 | Initiates Coverage On | → Overweight |
| 07/19/2021 | 468.86% | JP Morgan | → $38 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/11/2023 | 64.67% | 瑞士信贷 | → 11 美元 | 重申 | 中性 → 中性 |
| 05/12/2023 | 64.67% | 瑞士信贷 | → 11 美元 | 重申 | 中性 → 中性 |
| 03/17/2023 | 64.67% | 瑞士信贷 | 12 美元 → 11 美元 | 维护 | 中立 |
| 01/03/2023 | 184.43% | 富国银行 | → 19 美元 | 升级 | 重量相等 → 超重 |
| 2022 年 10 月 13 日 | 229.34% | 瑞银（UBS） | → 22 美元 | 启动覆盖开启 | → 购买 |
| 08/15/2022 | 199.4% | 杰富瑞 | → 20 美元 | 启动覆盖开启 | → 购买 |
| 2022 年 12 月 5 日 | 214.37% | 派珀·桑德勒 | 40 美元 → 21 美元 | 维护 | 超重 |
| 04/28/2022 | 184.43% | 瑞士信贷 | → 19 美元 | 启动覆盖开启 | → 中立 |
| 2022 年 10 月 2 日 | 184.43% | 富国银行 | → 19 美元 | 启动覆盖开启 | → 重量相等 |
| 2021 年 10 月 14 日 | 199.4% | SVB Leerink | → 20 美元 | 启动覆盖开启 | → 市场表现 |
| 07/19/2021 | 349.1% | 古根海姆 | → 30 美元 | 启动覆盖开启 | → 购买 |
| 07/19/2021 | 498.8% | 派珀·桑德勒 | → 40 美元 | 启动覆盖开启 | → 超重 |
| 07/19/2021 | 468.86% | 摩根大通 | → 38 美元 | 启动覆盖开启 | → 超重 |
What is the target price for Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics（GLUE）的目标价格是多少？
The latest price target for Monte Rosa Therapeutics (NASDAQ: GLUE) was reported by Credit Suisse on August 11, 2023. The analyst firm set a price target for $11.00 expecting GLUE to rise to within 12 months (a possible 64.67% upside). 6 analyst firms have reported ratings in the last year.
瑞士信贷于2023年8月11日公布了Monte Rosa Therapeutics（纳斯达克股票代码：GLUE）的最新目标股价。这家分析公司将目标股价定为11.00美元，预计GLUE将在12个月内升至11.00美元（可能上涨64.67％）。去年有6家分析公司公布了评级。
What is the most recent analyst rating for Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics（GLUE）的最新分析师评级是多少？
The latest analyst rating for Monte Rosa Therapeutics (NASDAQ: GLUE) was provided by Credit Suisse, and Monte Rosa Therapeutics reiterated their neutral rating.
Monte Rosa Therapeutics（纳斯达克股票代码：GLUE）的最新分析师评级由瑞士信贷提供，Monte Rosa Therapeutics重申了其中性评级。
When is the next analyst rating going to be posted or updated for Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics（GLUE）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monte Rosa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monte Rosa Therapeutics was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Monte Rosa Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Monte Rosa Therapeutics的最后一次评级是在2023年8月11日提交的，因此你应该预计下一个评级将在2024年8月11日左右公布。
Is the Analyst Rating Monte Rosa Therapeutics (GLUE) correct?
分析师对蒙特罗莎治疗公司（GLUE）的评级正确吗？
While ratings are subjective and will change, the latest Monte Rosa Therapeutics (GLUE) rating was a reiterated with a price target of $0.00 to $11.00. The current price Monte Rosa Therapeutics (GLUE) is trading at is $6.68, which is within the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的蒙特罗莎治疗公司（GLUE）评级得到了重申，目标股价为0.00美元至11.00美元。Monte Rosa Therapeutics（GLUE）目前的交易价格为6.68美元，在分析师的预测区间内。